| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
1 company
Bredt David is a Chief Scientific Officer at Rapport Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 2 sells.
Estimated insider holdings value: $15.1M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15, 2025 | RAPP Rapport Therapeutics, Inc. | Chief Scientific Officer | Sell | 8,500 | $9.57 | $81,310.15 | -1.8% | +52.4% | +255.9% | |
| Mar 14, 2025 | RAPP Rapport Therapeutics, Inc. | Chief Scientific Officer | Sell | 8,500 | $10.85 | $92,205.45 | -1.8% | +6.0% | +164.9% |